Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

MLA

Prica, Anca, et al. “Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.” Blood, vol. 130, no. 1, Number 1 Supplement 1, Dec. 2017, p. 4673. EBSCOhost, https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673.

APA

Prica, A., Hay, A. E., Crump, M., Mittman, N., Shepherd, L. E., Meyer, R., Imrie, K., Risebrough, N. A., Djurfeldt, M. S., Chen, B. E., & Cheung, M. (2017). Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Blood, 130(1, Number 1 Supplement 1), 4673. https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Chicago

Prica, Anca, Annette E Hay, Michael Crump, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, Kevin Imrie, et al. 2017. “Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.” Blood 130 (1, Number 1 Supplement 1): 4673. doi:10.1182/blood.V130.Suppl_1.4673.4673.